Canadian Respiratory Journal · 2018 · 14 citations · 10 references
PharmacyInfectious DiseasesAntimicrobial PharmacotherapyAntimicrobial StewardshipClinical Decision SupportAntibiotic ResistanceAntimicrobial Agent SelectionHospital Antimicrobial StewardshipNosocomial InfectionsRespiratory Pathogen DiagnosticsAntimicrobial Drug MonitoringClinical Outcome DocumentationClinical Outcome MeasurementInpatient StatusMedical Records ReviewProcalcitonin-guided Antibiotic De-escalationRespiratory Tract Infection TreatmentSafety Of Antibiotic De-escalation
Objective . To determine whether results of the nasopharyngeal FilmArray respiratory panel (NP-FARP) influenced antibiotic decisions. Methods . We reviewed the medical records of nonintensive care unit (ICU) inpatients that had an NP-FARP performed at our institution between June 2013 and June 2014. The inpatient records were reviewed 48 hours after the NP-FARP for the following data: demographic information; NP-FARP, serum procalcitonin, and methicillin-resistant Staphylococcus aureus nasal swab (MRSA NS) results; antibiotics prior and post-48 hours of the NP-FARP result; and the current immunosuppression status. Clinical outcome data were not obtained. Patients were categorized into those who had a positive (+) or a negative (−) NP-FARP. We further subdivided these two categories into groups A, B, and C based on the antibiotic modifications 48 hours after their NP-FARP result. Group A included patients who were never initiated on antimicrobial therapy. Patients whose antibiotics were discontinued or deescalated were placed in group B. Patients with antibiotic escalation or continuation without change constituted group C. We compared and analyzed groups A, B, and C in the (+) and (−) NP-FARP cohorts. Results . A total of 545 patients were included. There were 143 (26%) patients with positive and 402 (74%) patients with negative NP-FARPs. Comparison of groups A, B, and C between those with a (+) and (−) NP-FARP were as follows: (+) A and (−) A, 28/143 (20%) and 84/402 (21%); (+) B and (−) B, 59/143 (41%) and 147/402 (37%); and (+) C and (−) C, 56/143 (39%) and 171/402 (43%), respectively. We found no statistically significant differences between groups (+) A versus (−) A, (+) B versus (−) B, and (+) C versus (−) C with respect to age, gender, MRSA NS result, procalcitonin result, or concurrent immunosuppression. Conclusion . In non-ICU inpatients, NP-FARP alone or in combination with procalcitonin or MRSA NS did not influence antibiotic decisions during the study period.
10
Association of Adverse Events With Antibiotic Use in Hospitalized Patients
Pranita D. Tamma, Edina Avdic, David X. Li et al. · JAMA Internal Medicine · 2017 · 778 citations · Full text
Benjamin S. Dangerfield, Andrew S. Chung, Brandon Webb et al. · Antimicrobial Agents and Chemotherapy · 2013 · 182 citations · Full text
Life Sciences, Infectious Diseases, Diagnostic Microbiology +16